Adtran expands ALM with deep PON assurance for FTTX network monitoring
Adtran today announced the extension of its ALM infrastructure assurance solution, enabling simple and cost-efficient fiber monitoring of passive optical networks (PON). Already widely deployed in other types of network architecture, the technology now provides deep PON assurance, enabling communication service providers (CSPs) to monitor their entire PON infrastructure for any faults or degradation. Until today, assuring PON networks was challenging and expensive. Now there’s a simple and cost-efficient way to leverage real-time insight so that maintenance teams can quickly locate and resolve issues before they affect customers. PON networks are critical for the delivery of high-speed connectivity to millions of homes and businesses. The ability to comprehensively monitor this essential part of the network will deliver major benefits in terms of performance, reliability and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230712070000/en/
Adtran’s ALM deep PON assurance technology is a unique solution that will provide CSPs with granular insight into their PON networks. (Photo: Business Wire)
“The evolution of our ALM device to include deep PON assurance marks a major milestone for the industry and for our company. It’s the first time since the merger of Adtran and ADVA that our combined technology teams have released a solution that shows the close synergies between the organizations,” said Christoph Glingener, CTO of Adtran. “We are major players in both the PON and fiber assurance spaces with rapidly growing market shares. By utilizing our expertise in these areas, we’ve developed a unique solution that could have an enormous impact on CSPs’ opex costs. For the first time, they will be able to both monitor and manage their PON networks in one pane of glass. This will provide CSPs with more insight and granular control than ever before. And because our deep PON assurance technology works through splitters, we’re able to keep capex costs low.”
Adtran’s ALM technology for in-service fiber monitoring is available immediately and can be easily integrated into existing fiber-to-the-home, fiber-to-the-business or any other FTTX network. The non-intrusive, service-agnostic deep PON assurance solution eliminates the need for demarcation reflectors in the field, ensuring compatibility with any existing PON network while reducing operational complexity. Offering valuable insights into passive network quality, it acts like a radar to pinpoint the location of issues. Featuring fanless operation and low-power consumption, the ultra-compact ALM enhances operational efficiency and sustainability. CSPs can quickly check the status of their PON network through Adtran’s web-based GUI, Ensemble Controller network management platform or a dedicated mobile application for on-the-go access.
“Our ALM assurance platform is already recognized as the gold standard for fiber monitoring in optical networks. With our deep PON assurance innovation, we’re extending its benefits to many more customers, enabling FTTX network operators to dramatically shorten repair cycles and avoid unnecessary truck rolls. This breakthrough technology will transform how CSPs manage their PON infrastructure, enabling them to provide a better customer experience while reducing costs and improving sustainability,” commented Sander Jansen, GM of Infrastructure Monitoring at Adtran. “We’re excited to help our customers unlock the full potential of their PON networks and provide them with the real-time insights they need to optimize performance and reduce their carbon footprint.”
Further information on Adtran’s ALM deep PON assurance technology is available in these slides.
A supporting product video is also available to watch.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230712070000/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
